PDA

View Full Version : DIGNITY Study


Jackie07
06-25-2009, 01:04 PM
A lady from the DIGNITY study had contacted me. Below is our e-mail exchange. If you are interested in participating in the study, please contact her directly (see end of e-mails for her contact info.)

Hi Jackie,

Nice to hear from you! Thank you for getting back to me so quickly. Will you be having another MUGA in the near future?

About the HER2 Support group, yes that would be wonderful if you can help 'spread the word' and create awareness about this new trial. Any efforts you can provide are greatly appreciated. In the meantime, I will try to reach out to the webmaster as you've suggested.

Please let me know how I can be of any help to you.

All the best,
Jeannette
----- Original Message -----
From: Mrs. Jackie Swenson (mmtime_98@yahoo.com)
To: Jeannette Tighe (jtighe@medadvisory.net)
Sent: Thursday, June 25, 2009 11:53 AM
Subject: Re: Following up with you - DIGNITY Study for BC with recurrence to the chest wall


Hi Jeannette,

Thank you for your follow-up.

My MUGA score went down from the upper 50's to 51 after just 6 rounds (3weeks x 6) of TCH and 4 weekly Herceptin. It further went down to 48 after 2 months break.
I have not had a MUGA for over a year. But judging the way my ankles are swelling up, I am pretty sure the heart muscle function has not improved. I am not short of
breath or anything like that, but I did cut back much of my physical activities simply because I don't feel like doing anything.

I appreciate your effort in finding cures for this horrandous disease. I belong to the Her-2 support group - a very active Her-2 breast cancer support group. Would you
like me to forward your information there? The webmaster's name is Joe. I think you can either contact him or register yourself and post the research project.
The address is www.her2support.org (http://www.her2support.org)

Thanks again for writing.

Jackie07


From: Jeannette Tighe <jtighe@medadvisory.net>
To: mtime@sbcglobal.net
Sent: Wednesday, June 24, 2009 10:42:47 PM
Subject: Following up with you - DIGNITY Study for BC with recurrence to the chest wall

Hello Jackie,

I hope this email finds you well. I wanted to reach out to you to let you know that the study coordinator from the FL Cancer Institute has been trying to get in touch with you about this trial. I remember you saying that your scores were improving over the last year and so I am wondering if you would like me to tell the study coordinator that you are not interested at this time.

If you are still interested, please let me know a convenient date/time that she may give you a call to answer any questions you may have.

Look forward to hearing from you.

All the best,
Jeannette


Jeannette Tighe, Principal
MedAdvisoryllc www.medadvisory.net (http://www.medadvisory.net/)
O|F: 508.297.2439 | M: 508.498.8465

Jackie07
08-05-2009, 01:35 PM
Recurrent Chest Wall Cancer after Mastectomy -
New Breast Cancer Clinical Trial

http://origin.ih.constantcontact.com/fs046/1101822054034/img/172.jpg?a=1102660733912 (http://rs6.net/tn.jsp?et=1102660733912&s=1688&e=001GXHbxXhadBcqwLb3wmQVqk4JqM_wA0zYAoxVHPv6mJu_q 7Q_jlsNxGH-uGdg0GsawJHU5GzSRj4GKqkFYy5pmVcGFWJuc5hQl28QzDa4sK PGRigTEn-Dgn_sM7KiM0flrEemjZrHAPjHDeTCZ4nWkz-jTIEvstUfWiCCByYI6F_Ei3d-FLpUwQ==)

If you are experiencing breast cancer with recurrence to the chest wall (RCW) or know someone who is, you may be interested in this clinical trial, the DIGNITY Study. Researchers are conducting the trial to determine the effectiveness of a novel investigational drug used in combination with heat therapy for the treatment of recurrent chest wall cancer (RCW).

To participate in this trial, patients will:
- Have a documented recurrence of breast cancer on the chest wall (or its overlying skin)
- And have had: a mastectomy, radiation, and chemotherapy

CLICK HERE TO FIND OUT IF YOU ARE ELIBIBLE TO PARTICIPATE: http://www.surveymonkey.com/s.aspx?sm=ZwRugqNJUfmD4lBtU0bsYQ_3d_3d (http://rs6.net/tn.jsp?et=1102660733912&s=1688&e=001GXHbxXhadBcqwLb3wmQVqk4JqM_wA0zYAoxVHPv6mJu_q 7Q_jlsNxGH-uGdg0GsawJHU5GzSRj4GKqkFYy5pmVcGFWJuc5hQl28QzDa4sK PGRigTEn-Dgn_sM7KiM0flrEemjZrHAPjHDeTCZ4nWkz-jTIEvstUfWiCCByYI6F_Ei3d-FLpUwQ==)

SIGN UP HERE TO RECEIVE EMAIL UPDATES ABOUT THIS TRIAL:
http://survey.constantcontact.com/survey/a07e2jzbhkofxyrqwh8/start (http://rs6.net/tn.jsp?et=1102660733912&s=1688&e=001GXHbxXhadBca_WGmRp51NSekW-1Rm5HWyVDHYoFFzGKq8PfQM0ZQiz9sUxr0_-ysE_FNigcL9DURnHspV22iiR3mAkrG0fv-xcKKaYMjwGnT2xzRhsTr4MztIi1MumLg291RUovjO1DxXS2VAe Tb9zCtnr9sZl2snGRqxO3fOmLDEhIDkHrPHPQJHZ50Tb4EXguI YhADaB8=)
Email updates will include:
· A description of the investigational therapy and study requirements,
· Eligibility criteria,
· US trial site locations,
· An opportunity to:


request brochures,
talk to someone directly about your situation,
share information with friends, family, your support network and your physician,
ask questions about this trial.

Questions about this message? Please contact:
Jeannette Tighe at MedAdvisory
Phone: 508-297-2439
Email: jtighe@medadvisory.net


Kind regards,

Jeannette Tighe
Principal, MedAdvisory LLC
www.medadvisory.net (http://rs6.net/tn.jsp?et=1102660733912&s=1688&e=001GXHbxXhadBcbUt4RpeS7UoODp-XB4mcNQnQwFPsreMC3tHyuTC-QNncUGkCXvXsGxFUqCA_JxPe6ytwblROYahaQlUj8ELVI6r5Vi WSzptOgeCPdknRQlg==)
jtighe@medadvisory.net
508-297-2439
http://origin.ih.constantcontact.com/fs046/1101822054034/img/1.jpg?a=1102660733912

Forward email (http://ui.constantcontact.com/sa/fwtf.jsp?m=1101822054034&ea=mtime%40sbcglobal.net&a=1102660733912)
http://img.constantcontact.com/letters/images/safe_unsubscribe_logo.gif (http://visitor.constantcontact.com/d.jsp?v=001EYE_9pNc5E1B9ouq14EGJrqMhNLyRKrIuoRiT4S jct6QL31trJlgDw%3D%3D&p=un) This email was sent to mtime@sbcglobal.net by jtighe@medadvisory.net.
Update Profile/Email Address (http://visitor.constantcontact.com/d.jsp?v=001EYE_9pNc5E1B9ouq14EGJrqMhNLyRKrIuoRiT4S jct6QL31trJlgDw%3D%3D&p=oo) | Instant removal with SafeUnsubscribe (http://visitor.constantcontact.com/d.jsp?v=001EYE_9pNc5E1B9ouq14EGJrqMhNLyRKrIuoRiT4S jct6QL31trJlgDw%3D%3D&p=un)™ | Privacy Policy (http://ui.constantcontact.com/roving/CCPrivacyPolicy.jsp).
Email Marketing (http://www.constantcontact.com/index.jsp?cc=TEM_BusLet_002) by
http://img.constantcontact.com/letters/images/cc-logo-color-sm.gif (http://www.constantcontact.com/index.jsp?cc=TEM_BusLet_002) MedAdvisory LLC | 7 Glenn Road | North Easton | MA | 02356

http://rs6.net/on.jsp?t=1102660733912.0.1101822054034.1688&ts=S0408&o=http://ui.constantcontact.com/images1/s.gif

Jackie07
09-03-2009, 06:43 PM
If you are experiencing breast cancer with recurrence to the chest wall (RCW) or know someone who is, you may be interested in this clinical trial, the DIGNITY Study. Researchers are conducting the trial to determine the effectiveness of a novel investigational drug used in combination with heat therapy for the treatment of recurrent chest wall cancer (RCW).

To participate in this trial, patients will:
- Have a documented recurrence of breast cancer on the chest wall (or its overlying skin)
- And have had: a mastectomy, radiation, and chemotherapy

CLICK HERE TO FIND OUT IF YOU ARE ELIGIBLE TO PARTICIPATE: http://www.surveymonkey.com/s.aspx?sm=ZwRugqNJUfmD4lBtU0bsYQ_3d_3d (http://rs6.net/tn.jsp?et=1102675293088&s=1688&e=001SSxYc2w2jV2Kq5Hivg545GPd1xvd2mIbEx2-_jembYeEIMGlgKJKrYyty5_qb0bq3H6VfiyuYSwCpnnHBIcFUd 8Zngf55vvYkYa-SChexTC3D_R9PSK1aYP8iWA0D4ionQMKuFVuYrJwTO-DCieaUtR0jgXkCH2soq0sCQV5isA-nPzsFuJ58g==)

SIGN UP HERE TO RECEIVE EMAIL UPDATES ABOUT THIS TRIAL:
http://survey.constantcontact.com/survey/a07e2jzbhkofxyrqwh8/start (http://rs6.net/tn.jsp?et=1102675293088&s=1688&e=001SSxYc2w2jV1mxnFPqGCjom-D1H9Pg8K3mZLHVlT5qYaeHIdKk2-U-tiqe5kUilC_U2fMQv_GI6j7LaHzIvF3X9QopwU7nc_9EQxgfbA jsxk9ixmU5Q4b7j_92njWVzO46pS_AMSsiUMsvyaxXvuRKthVh Ww26BwoJfib92U-Lm4OfkjQhnEp7yWfoUmfJBLn1TTOuH6OFoM=)
Email updates will include:
· A description of the investigational therapy and study requirements,
· Eligibility criteria,
· US trial site locations,
· An opportunity to:


request brochures,
talk to someone directly about your situation,
share information with friends, family, your support network and your physician,
ask questions about this trial.

Questions about this message? Please contact:
Jeannette Tighe at MedAdvisory
Phone: 508-297-2439
Email: jtighe@medadvisory.net


Kind regards,

Jeannette Tighe
Principal, MedAdvisory LLC
www.medadvisory.net (http://rs6.net/tn.jsp?et=1102675293088&s=1688&e=001SSxYc2w2jV3Nawup9UZc86Rr2R5HMRZeULFmM0OhUFLA0 Wo24QPx8dD5-jRPWI6jO-s2Ixhk1bia8M9KvUudq1CDwOPEC-zTkT4ko-FqDhufyigtLnsb2g==)
jtighe@medadvisory.net
508-297-2439